MY LIFE IN SCIENCE SEMINAR SERIES | GENEVIÈVE ALMOUZNI
In keeping with CRG’s commitment to support Equality, Diversity and Inclusion (EDI), the Gender Balance Committee is launching the new “My life in Science” seminar series, aiming to provide inspirational role models of successful scientists and their experience on how they managed to negotiate professional and life challenges in their career.
The first of these events will be held on October 23th from 12.00 to 13:00 fully virtual with a scientific seminar given by Dr. Geneviève Almouzni, Head of the Chromatin Dynamics team Research center of Institute Curie and Member of the Science Academy in France.
Geneviève ALMOUZNI, PhD (EMBO member, Member of the French Academy of Sciences, fellow of the American Association for the Advancement of Sciences, Director of the Research Center of the Institut Curie from sept 2013 to September 2018 and honorary director since then) is director of research exceptional class at the CNRS. She is Principal Investigator of the Chromatin dynamics team in the Nuclear dynamics research Unit (UMR3664 CNRS/Institut Curie) since 1999. She is a world leader in understanding genome organization and function during development and disease in particular in cancer. She has combined biochemistry, cell biology and physical approaches with advanced imaging to explore chromatin dynamics. Overall, G. Almouzni authored more than 220 publications and deposited 5 patents. Active in the field of Epigenetics and European actions, she coordinated the EpiGeneSys Network of Excellence to move epigenetics towards systems biology. She is highly engaged in promoting young scientist career. She received prestigious grants (ERC Advanced Grants) and awards including Woman in Sciences FEBS / EMBO (2013) and the grand prix FRM (2014). She served on the EMBO Council (Vice-chair in 2014), chair of the alliance EU-LIFE, she co-chairs the European FETFlagship initiative LifeTime with Prof. N. Rajewski at the MDC Berlin.
All are welcome and encouraged to attend the seminar.